Atrial Fibrillation Trial, Recruiting NCT06578793 Sponsor: Second Xiangya Hospital of Central South University Condition: Atrial Fibrillation
Back to Atrial Fibrillation

Atrial Fibrillation Trial, Recruiting

NCT06578793
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged between 18 and 80 years
  • People with symptomatic, persistent atrial fibrillation (an irregular heartbeat lasting more than 7 days without returning to normal on its own) that has been present for at least 6 months, with at least two episodes in the past 6 months even after treatment to restore normal rhythm
  • People whose atrial fibrillation has not responded well to, or who have had problems tolerating, at least one type of heart rhythm medication
  • People diagnosed with heart failure where an ultrasound of the heart shows the heart is pumping at 40% or less of its normal capacity
  • People who are willing to receive either medication or surgical treatment as part of the trial
  • People who are willing to follow all study requirements throughout the trial and during follow-up, and to sign a consent form
  • People who are physically able to complete a 6-minute walking test
  • Women who could become pregnant must have a negative pregnancy test result before joining

Who may not be able to join:

  • People who have a blood clot in the upper left chamber of the heart
  • People whose left upper heart chamber is enlarged beyond a certain size, as measured by ultrasound, MRI, or CT scan
  • People with significant inborn heart abnormalities or other medical conditions that the research team considers unsuitable for participation
  • People whose atrial fibrillation is caused by a treatable or temporary condition, such as thyroid disease, pericarditis (inflammation around the heart), recent surgery, injury, or alcohol-related causes
  • People with heart valve disease that requires surgery
  • People with blocked heart arteries that require surgery or a procedure to treat them
  • People who have previously had a procedure to deliberately block the heart's electrical relay node (atrioventricular node ablation)
  • People with liver failure
  • People with kidney failure who require dialysis
  • People who are unable to take blood-thinning medications (anticoagulation therapy)
  • People who are currently taking part in another clinical trial of an experimental drug or device
  • People with severe lung disease
  • People who have previously had a catheter-based procedure to treat atrial fibrillation inside the left upper chamber of the heart
  • People who have had a blood clot-related event, such as a stroke, within the past 90 days
  • People who are pregnant

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: 3973183686

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Second Xiangya Hospital of Central South University
Registry
ClinicalTrials.gov
Start date
1 August 2024
Est. completion
31 July 2025

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Freedom from Atrial Fibrillation/Atrial Flutter (AT/AF) Recurrence; Change in NT-proBNP Levels; Change in Left Ventricular Ejection Fraction (LVEF); Change in 6-Minute Walk Test Distance; Change in NYHA Functional Class

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov